If you ask someone outside of pharma what a Medical Science Liaison does, you will get one of two answers. The first is a blank stare. The second is some variation of "they're like sales reps, but for science." Both responses are wrong, but the second one is more damaging, because it shapes how organizations invest in the role — and, critically, how they fail to.
From the outside, the MSL role looks like a scientific sales job. From the inside, it is closer to being a field-based scientific consultant who happens to work for a pharmaceutical company. MSLs do not carry a bag. They do not have a quota. They do not close deals. They engage in peer-to-peer scientific exchange with physicians, researchers, and institutional decision-makers — conversations that are governed by a fundamentally different set of rules than anything on the commercial side of the business.
The gap between perception and reality matters because it determines the quality of support MSLs receive. When leadership views the MSL function through a commercial lens, the result is commercial tools, commercial metrics, and commercial expectations applied to a non-commercial role. The downstream effects are predictable: MSLs spend their days fighting systems designed for someone else's workflow, documenting their work in formats that obscure rather than illuminate, and defending the value of activities that do not fit neatly into a sales dashboard.
This article is an attempt to correct the record. Not with talking points, but with granular detail about what an MSL's day actually looks like — the scientific exchanges, yes, but also the logistics, the administrative burden, the travel, the no-shows, and the quiet strategic work that never appears in a KPI report.
The MSL Role in Context
MSLs report into Medical Affairs, not Commercial. This single fact shapes nearly everything about the role, and yet it is the detail most frequently misunderstood by people outside the function. Medical Affairs sits between R&D and the commercial organization — it is the part of a pharma company responsible for scientific communication, evidence generation, and medical strategy. When an MSL has a conversation with a physician, that conversation is governed by medical compliance frameworks, not promotional guidelines. An MSL can discuss off-label data, emerging clinical evidence, and ongoing trial results in ways that a sales representative legally cannot.
This distinction is not bureaucratic. It is the reason physicians agree to meet with MSLs in the first place. A department chair at an academic medical center has no interest in a product pitch. They will, however, make time for a substantive scientific discussion with someone who has read their research, understands their clinical challenges, and can offer data they have not yet seen. The peer-to-peer dynamic is the entire value proposition of the MSL role, and it depends on the MSL's independence from commercial objectives.
The typical MSL holds a PhD, PharmD, MD, or equivalent advanced degree. Many have published research. Some have completed postdoctoral fellowships. They are hired for their scientific depth and their ability to engage credibly with the medical community — not for their selling skills. Compensation reflects this: MSLs are salaried professionals without commission structures, and their performance is evaluated on scientific engagement quality, not revenue metrics.
The role has evolved significantly over the past two decades. In the early 2000s, many companies treated MSL teams as a nice-to-have — a small group of scientifically trained professionals who could fill a niche between medical information and the field force. Today, MSL teams are a strategic priority. Companies are expanding their MSL headcounts, investing in MSL-specific training programs, and increasingly relying on MSLs for activities that directly influence clinical development and medical strategy. The role has grown, but as we will see, the infrastructure supporting it has not kept pace.
A Typical Day
No two MSL days are identical, and that is part of what makes the role both appealing and exhausting. But there are patterns. What follows is a representative day for a field-based MSL in a mid-size to large pharma company — not an idealized version, but the actual rhythm of the work.
Morning: 7:00 AM - 10:00 AM
The day starts at home, usually before any meetings. Email triage comes first. An MSL's inbox is a mix of internal communications — medical affairs updates, compliance reminders, invitations to cross-functional meetings — and external correspondence with KOLs. There might be a response to a meeting request sent last week, a follow-up question from a physician about a data set discussed in a previous interaction, or a medical information request routed from the company's call center.
Next comes CRM documentation from yesterday's interactions. Most companies require MSLs to log every HCP interaction within 24 hours. This means opening the CRM — typically Veeva or Salesforce — and entering details about each meeting: who was present, what topics were discussed, what materials were shared, and what insights were captured. For a day with three meetings, this can take 45 minutes to an hour. The CRM forms are designed for data capture, not narrative, so the MSL is translating a nuanced scientific conversation into dropdown menus and text fields that strip away most of the context.
Then comes pre-call preparation. Today's first meeting is with a community oncologist who has been on the MSL's target list for six months. The MSL checks PubMed for any new publications from this physician. They review ClinicalTrials.gov to see if the physician has enrolled patients in any relevant studies. They skim their own CRM notes from the last interaction three months ago to refresh their memory on what was discussed and what the physician's key interests were. They pull up the latest data from the company's clinical program — there was a poster at a recent conference that is directly relevant to this physician's patient population. All of this research happens across four or five browser tabs and the CRM, none of which talk to each other.
Mid-Morning: 10:00 AM - 12:00 PM
The first HCP meeting. The MSL drives 40 minutes to a community oncology practice, checks in at the front desk, and waits. Physicians run late. Sometimes the wait is five minutes. Sometimes it is thirty. Sometimes the meeting gets canceled altogether because the physician was called into an emergency. Today, the MSL waits fifteen minutes before being shown to a small conference room.
The meeting itself is a scientific exchange. The MSL opens by referencing the physician's recent experience with a particular patient population — something the physician mentioned in their last interaction. This is not a presentation. There are no slides unless the physician asks to see specific data. The MSL shares the recent poster data, walks through the key endpoints, and asks for the physician's perspective on how these results apply to the patients they see in their community practice. The physician pushes back on one of the secondary endpoints, noting that the patient population in the trial does not reflect what they see in clinic. This is exactly the kind of insight the MSL is listening for.
The conversation lasts twenty minutes. It covers the new data, the physician's clinical experience with the product, their concerns about a competing therapy that is gaining formulary access in the region, and a question about an ongoing Phase III trial that the physician is considering referring patients to. The MSL makes a mental note of each of these threads. Before leaving, they confirm a follow-up: the MSL will send a published review article the physician asked about and will check on the trial enrollment status.
Midday: 12:00 PM - 1:30 PM
Lunch is functional. Today, the MSL has organized a lunch-and-learn at a community hospital — a thirty-minute presentation to a group of residents and attending physicians on disease-state education in the MSL's therapeutic area. This is not a product presentation. The content has been through medical-legal-regulatory review and is focused on the science of the disease: pathophysiology, treatment landscape, emerging evidence. The MSL presents, takes questions, and uses the opportunity to identify physicians in the group who are particularly engaged and might warrant future one-on-one interactions.
Between the presentation and the next appointment, the MSL grabs a sandwich in the car and makes a quick call to the commercial representative who covers the same territory. This coordination is carefully managed. The MSL and the sales rep can share logistical information — the physician's scheduling preferences, the best time to visit a particular office — but they cannot discuss the substance of the MSL's scientific interactions. The wall between promotional and non-promotional activity is real and enforced, and both sides know where the line is.
Afternoon: 1:30 PM - 4:00 PM
The drive to the next appointment is an hour and fifteen minutes. This is typical. MSLs cover large geographies — a single territory might span an entire state or a cluster of metropolitan areas across state lines. Windshield time is not dead time; it is when much of the MSL's non-field work happens. Today, the MSL takes a call with their Medical Affairs director to discuss an upcoming advisory board. The director wants input on which KOLs to invite, and the MSL — who knows these physicians personally — provides perspective on who would be genuinely useful versus who would simply be a name-brand panelist.
After the call, the MSL spends the remaining drive time on territory planning. Next week has three open days, and the MSL needs to decide which KOLs to prioritize. There is a Tier 1 KOL at a university hospital who has not been contacted in two months. There is a rising investigator who just published a paper in a high-impact journal. There is a formulary committee meeting coming up at a regional health system, and the MSL wants to connect with the committee chair beforehand. All of this prioritization is happening in the MSL's head, occasionally cross-referenced with a spreadsheet on their laptop at the next stop.
The afternoon appointment is a no-show. The KOL's office contacts the MSL twenty minutes before the scheduled meeting — the physician has been pulled into a procedure and will not be available. This happens regularly. MSLs build buffer into their schedules because cancellations are not the exception; they are a recurring feature of the work. The MSL pivots. There is another physician at a nearby practice who the MSL has been trying to connect with. The MSL makes a cold drop-in — stopping by the office without an appointment, leaving a business card, and asking the front desk if the physician has a few minutes. Today, the physician does. The resulting ten-minute hallway conversation yields a commitment to a formal meeting next month.
Late Afternoon: 4:00 PM - 6:00 PM
The last scheduled interaction of the day is at an academic medical center with a KOL the MSL has been cultivating for over a year. This is a different dynamic entirely. The physician is a rising star — early career, prolific publisher, increasingly visible at congresses. The MSL's relationship with this KOL is long-term and strategic. Today's conversation is not about a specific data set. It is about the KOL's research direction, their interest in serving on an upcoming advisory board, and their perspective on where the treatment landscape is headed over the next three to five years.
These relationship-building interactions are harder to quantify in a CRM but are among the most valuable things an MSL does. A Tier 1 KOL who trusts the MSL will share candid assessments of the competitive landscape, provide early signals about shifts in clinical practice, and advocate for the company's science in settings where the company has no other presence — guideline committees, peer review, grand rounds. Building that trust requires consistent, credible engagement over months and years, not transactional check-ins.
Evening: 6:00 PM - 8:00 PM
The drive home is forty-five minutes. Once home, there is still work to do. CRM documentation for today's interactions cannot wait until tomorrow — the details will fade, and the compliance clock is ticking. The MSL opens the CRM and logs three interactions: the community oncologist, the lunch-and-learn, and the academic KOL. For each, they enter the topics discussed, materials shared, insights captured, and follow-up actions. The community oncologist's feedback about the secondary endpoint and the formulary concern get documented as insights. The academic KOL's interest in the advisory board gets flagged for the Medical Affairs director.
Between CRM entries, the MSL reviews a clinical trial publication that landed in their inbox that afternoon — a competitor's Phase III results in the same indication. They skim the abstract, note the key findings, and mentally prepare for the questions their KOLs will inevitably have when they discuss these results at upcoming meetings. Tomorrow, they will read the full paper.
By 8:00 PM, the laptop closes. Total driving time today: approximately three hours. Total time in HCP meetings: perhaps ninety minutes. Total time on administrative work, preparation, and documentation: roughly four hours. This ratio is the reality of the MSL role, and it is why the end-to-end MSL workflow deserves more scrutiny than it typically receives.
The Hidden Time Sinks
The day described above is representative, but it understates the cumulative weight of the administrative burden. When you survey MSLs about where their time actually goes, the same categories appear consistently — and the percentages are sobering.
CRM documentation and data entry. Industry surveys consistently place this at 30 to 40 percent of an MSL's productive time. Every interaction must be logged. Every insight must be categorized. Every follow-up action must be tracked. The CRMs in use were designed for sales force automation and have been adapted — poorly, in most cases — for medical use. The result is a documentation process that feels like an exercise in translating meaningful scientific work into a format that satisfies the system's requirements without actually preserving what happened. MSLs know their notes are rarely read by anyone upstream, which further erodes motivation to invest in detailed documentation.
Manual KOL research. Before every significant interaction, an MSL needs to know what their KOL has been doing. New publications, new trial enrollments, new conference presentations, changes in institutional affiliation, recent industry payments. This information is publicly available but scattered across PubMed, ClinicalTrials.gov, Open Payments, conference websites, and institutional directories. An experienced MSL can compile a KOL dossier in 30 to 60 minutes. Multiply that across a territory of 80 to 120 KOLs, and the math becomes untenable. Profiles go stale within weeks.
Territory planning in spreadsheets. Most MSLs manage their territory plans in Excel or PowerPoint. They manually track which KOLs have been seen, which are overdue, which have shifted in priority. They plan routes using Google Maps and institutional knowledge. They present their plans to management in quarterly business reviews, often spending days assembling the deck. These plans are static snapshots that are out of date before the presentation ends.
Travel logistics. MSLs are among the most-traveled professionals in pharma. A territory that spans several hundred miles means hours of driving each week, flights for cross-territory meetings, hotel bookings for multi-day field trips. Travel planning itself is a recurring time sink — optimizing routes, coordinating schedules around physician availability, and managing the inevitable disruptions when a KOL cancels and the day's itinerary needs to be rebuilt on the fly.
Internal meetings and home office weeks. Most MSL teams have designated home office weeks — typically one week per month — filled with team meetings, training sessions, compliance reviews, cross-functional alignment calls, and strategic planning. These weeks are necessary but come at the cost of field time. Even during field weeks, MSLs are pulled into virtual meetings with increasing frequency. The post-COVID expansion of virtual meeting culture has, paradoxically, made the in-person MSL role harder by adding a layer of remote obligations on top of an already full field schedule.
Reactive work. Medical information requests from physicians arrive unpredictably and require timely responses. Congress preparation — reviewing abstracts, building pre-congress KOL engagement plans, attending and documenting sessions — consumes weeks of calendar time around major conferences. Advisory board logistics — identifying candidates, managing invitations, preparing discussion guides, documenting outputs — can absorb an MSL's attention for months. None of this reactive work appears on the schedule until it does, and it routinely displaces planned field activity.
The cumulative effect is a role where the highest-value activity — direct scientific engagement with KOLs — occupies a minority of the MSL's time. This is the structural problem that the current tool landscape has failed to address. The tools exist to track what MSLs have done. They do not exist to reduce the time MSLs spend on work that should not require a doctoral degree.
What Makes a Great MSL
The job description for an MSL role will list qualifications: advanced degree, therapeutic area expertise, communication skills, willingness to travel. These are necessary but not sufficient. The MSLs who are genuinely exceptional share a set of qualities that are harder to screen for and harder to teach.
Scientific credibility that cannot be faked. The peer-to-peer dynamic only works if the physician genuinely perceives the MSL as a peer. This means the MSL must be able to engage with the nuances of clinical data — not just recite top-line results, but discuss study design, statistical methodology, endpoint selection, and real-world applicability. A physician who detects that the MSL is reading from a script or lacks genuine understanding will politely end the meeting and decline future ones. Scientific credibility is earned in the first five minutes and maintained across every subsequent interaction.
Relationship building measured in years, not meetings. The most valuable KOL relationships are the product of consistent, trust-building engagement over extended periods. A great MSL understands that the first several interactions with a new KOL are about listening and establishing credibility, not delivering value. They remember details from previous conversations. They follow up on commitments without fail. They bring relevant information that demonstrates they have thought about the physician's specific interests and challenges. Over time, this consistency transforms a professional acquaintance into a genuine scientific partner — someone who will take the MSL's calls, share candid feedback, and advocate for the company's science when it merits advocacy.
The ability to listen for strategic insights. Any MSL can deliver information. Great MSLs are distinguished by what they bring back. During a thirty-minute conversation, a physician might mention that their institution is considering a formulary change, that a colleague has expressed concerns about a particular safety signal, or that the local treatment pattern for a specific patient subgroup differs from what clinical trials would predict. Each of these is a strategic insight that could inform the company's medical strategy, clinical development program, or competitive response. Recognizing these moments requires not just scientific knowledge but strategic awareness — understanding what the company needs to know and why a particular data point matters.
Comfort with ambiguity and constant reprioritization. The MSL schedule is a suggestion, not a contract. Meetings cancel. KOLs reschedule. Urgent medical information requests arrive. A competitor's trial results drop, and suddenly every KOL in the territory wants to discuss them. A great MSL operates with a plan but holds it loosely, pivoting without frustration when the day's priorities shift. This requires a particular temperament — one that finds energy in variety rather than stability, and that can maintain focus and preparation quality even when the plan changes hourly.
Disciplined time management across competing priorities. An MSL managing a territory of 100 KOLs across a multi-state region, with obligations for congress preparation, advisory board support, medical information responses, and internal reporting, faces a resource allocation problem that would challenge any strategist. The great MSLs are rigorous about prioritization. They know which KOLs to invest deep time in and which to maintain through lighter touchpoints. They protect their field days from internal meeting creep. They batch their administrative work rather than letting it fragment their field time. And they push back — diplomatically but firmly — when the organization's demands threaten to crowd out the field engagement that is the MSL's primary purpose.
How the Role Is Changing
The MSL role in 2026 looks meaningfully different from what it was even five years ago. Several converging forces are reshaping the work, and they are worth understanding because they define what MSLs will need — from their organizations and from their tools — going forward.
Virtual engagement is now permanent. The pandemic forced MSL teams to adopt virtual interactions almost overnight, and the results were surprising. Many KOLs, particularly those at academic medical centers with packed clinical schedules, found that a focused twenty-minute video call was more convenient than an in-person office visit that required waiting room time and scheduling gymnastics. Virtual interactions will never replace in-person engagement for relationship building and complex scientific discussions, but they have become a permanent part of the MSL's toolkit. The best MSL teams now deploy a hybrid model — in-person for Tier 1 KOLs and high-value interactions, virtual for maintenance touchpoints, follow-ups, and time-sensitive scientific exchanges. This creates new operational complexity: managing two parallel engagement channels, each with its own scheduling norms and documentation requirements.
Growing emphasis on insights and real-world evidence. Medical Affairs organizations are increasingly positioning themselves as generators of strategic intelligence, not just scientific communicators. MSLs are being asked to capture more detailed insights, to identify opportunities for real-world evidence studies, and to contribute to evidence generation plans that support the product lifecycle. This elevates the role but also expands the scope of work. An MSL who was hired to have scientific conversations is now expected to be a field-based strategist, an evidence planning contributor, and a data collector — often without additional time or resources to support the expanded mandate.
MSL teams are getting larger. Companies across the industry are investing more in Medical Affairs field teams. Headcount is growing, particularly in oncology, immunology, rare disease, and cell and gene therapy. This growth reflects a recognition that MSLs drive value that commercial field teams cannot — particularly in therapeutic areas where the science is complex, the treatment landscape is evolving rapidly, and physician decisions are driven more by clinical evidence than by promotional messaging. Larger teams, however, create new management challenges: consistency of engagement quality, knowledge sharing across the team, and visibility into territory-level performance.
Increasing demand for data-driven territory planning. The era of territory planning based purely on institutional knowledge and inherited spreadsheets is ending. Medical Affairs leaders want to see engagement plans backed by data — publication trends, trial activity, prescribing patterns, competitive intelligence. They want to identify KOLs who are emerging before they appear on everyone's radar. They want to optimize coverage across large territories in ways that account for strategic priority, geographic efficiency, and engagement history. This demand is real, but the tools to support it have lagged. Most MSL teams are still building these analyses manually, one KOL at a time.
The technology gap is widening. Here is the central tension. The MSL role is expanding in scope, complexity, and strategic importance. The tools available to MSL teams are, for the most part, still adapted versions of sales force automation platforms. They were not designed for scientific engagement workflows, for KOL profiling, for insight synthesis, or for the kind of data-rich territory planning that Medical Affairs now demands. Platforms like Bionara are designed specifically for how MSLs actually work — not how a CRM vendor imagines they work. But broadly, the industry is still in the early innings of building technology that matches the sophistication of the role it is meant to support.
The MSLs who will thrive in this evolving landscape are the ones who can balance the expanding strategic mandate with the operational discipline the role has always required — and who work within organizations that invest in the infrastructure to make that balance possible. Companies that treat MSL technology as an afterthought will find their field teams spending even more time on manual work as the role's demands grow. Those that invest in purpose-built platforms will see the opposite: MSLs who spend more of their time on the scientific engagement and strategic insight generation that justifies the role's existence. For organizations evaluating what this shift looks like in practice, our case studies provide concrete examples.
Key Takeaways
- MSLs are field-based scientific consultants, not scientific sales reps. They report to Medical Affairs, engage in non-promotional peer-to-peer scientific exchange, and are evaluated on scientific credibility and strategic insight — not revenue. This distinction shapes every aspect of the role.
- Direct KOL engagement occupies a minority of the MSL's day. Between CRM documentation, manual KOL research, territory planning, travel, and internal meetings, the highest-value activity — scientific exchange — is routinely crowded out by administrative work.
- CRM documentation alone consumes 30 to 40 percent of productive time. The systems in use were designed for sales workflows and adapted for medical use, resulting in documentation that satisfies compliance requirements but fails to preserve the strategic value of what MSLs learn in the field.
- Great MSLs are defined by their listening, not their presenting. Scientific credibility gets you in the room. The ability to recognize strategic insights during a conversation — and to build trust over months and years of consistent engagement — is what makes an MSL genuinely valuable to the organization.
- The role is expanding faster than the tools supporting it. Virtual engagement, real-world evidence generation, data-driven territory planning, and larger team sizes are all increasing the MSL's scope of work. Without purpose-built technology, the administrative burden will grow proportionally.
- The perception gap has real consequences. When organizations misunderstand the MSL role — treating it as a variant of sales rather than a distinct scientific function — they invest in the wrong tools, measure the wrong metrics, and ultimately undermine the value their MSL teams could deliver.